Non-interventional Surveillance Study (NIS) on First-line (FL) Bevacizumab (Avastin) in Combination With Carboplatin/Paclitaxel in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Peritoneal Neoplasms
Both
Peritoneal Neoplasms
Trial Information
Non-interventional Surveillance Study (NIS) on First-line (FL) Bevacizumab (Avastin) in Combination With Carboplatin/Paclitaxel in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Newly diagnosed advanced epithelial ovarian cancer, fallopian tube carcinoma or
primary peritoneal cancer with indication for a first-line carboplatin/paclitaxel
chemotherapy in combination with Avastin
Exclusion Criteria:
- Contraindications to Avastin according to Summary of Product Characteristics
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Efficacy: Progression-free survival
Outcome Time Frame:
up to approximately 27 months
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Germany: Paul-Ehrlich-Institut
Study ID:
ML27765
NCT ID:
NCT01697488
Start Date:
February 2012
Completion Date:
March 2017
Related Keywords:
- Peritoneal Neoplasms
- Neoplasms
- Peritoneal Neoplasms
Name | Location |
|---|
